{"id":"NCT00804141","sponsor":"Bausch Health Americas, Inc.","briefTitle":"Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation","officialTitle":"An Open-Label Study to Evaluate the Long-Term Safety of Subcutaneous MOA-728 for Treatment of Opioid-Induced Constipation in Subjects With Nonmalignant Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12-03","primaryCompletion":"2010-09-20","completion":"2010-09-20","firstPosted":"2008-12-08","resultsPosted":"2019-10-18","lastUpdate":"2019-10-18"},"enrollment":1040,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Constipation"],"interventions":[{"type":"DRUG","name":"N-methylnaltrexone bromide (MOA-728)","otherNames":["Relistor"]}],"arms":[{"label":"MOA-728 12 mg QD","type":"EXPERIMENTAL"}],"summary":"This study is designed to evaluate the long-term safety and tolerability of the subcutaneous (SC) injection form of N-methylnaltrexone bromide (MOA-728) for the treatment of opioid-induced constipation in participants with nonmalignant pain. The study consists of a 2-week screening period, a 48-week open-label treatment period and a 2 week follow-up period. Participants will need to agree to self-administer SC injections, complete daily diaries, and check-in via a daily telephone call during the study.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"Baseline up to Week 50","effectByArm":[{"arm":"MOA-728 12 mg QD","deltaMin":817,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":120,"countries":["United States","Australia","Canada","Colombia","South Korea","Spain"]},"refs":{"pmids":["21429809"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3200K1-3358&StudyName=Study%20Evaluating%20Long-Term%20Safety%20Of%20MOA-728%20In%20Subjects%20With%20Opioid-Induced%20Constipation"]},"adverseEventsSummary":{"seriousAny":{"events":104,"n":1034},"commonTop":["Abdominal pain","Diarrhoea","Nausea","Hyperhidrosis","Vomiting"]}}